Gene therapy combined with radiotherapy for brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I study aims to determine the maximum tolerated dose of an oncolytic adenovirus combined with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma. Eligible patients will undergo tumor resection, followed by injection of the modified adenovirus into the resection cavity and any remaining tumor tissue. The treatment is further supplemented with oral prodrug therapy and monitored for 30 days before the next line of anti-cancer therapy begins. The study focuses on assessing safety and tolerability of this innovative approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects with radiologic evidence of intracranial recurrence or progression of a previously diagnosed high-grade astrocytoma.

   To be eligible for this trial, the subjects must have:
   * Histologically documented glioblastomas or anaplastic astrocytoma prior to the debulking surgery that is suspicious to have progressed on imaging. An interval of at least 3 months must have elapsed since the completion of the most recent course of radiation while at least 4 weeks must have elapsed since the completion of a non-nitrosourea containing chemotherapy regimen and at least 6 weeks since the completion of a nitrosourea containing chemotherapy regimen.
   * Patients must be ≥ 18 years of age, able to provide informed consent and express a willingness to meet all the expected requirements of the protocol for the duration of the study.
   * Must have recovered from toxicity (grade 2 or less) of prior therapy.
   * Eligible for partial or total resection of the recurrent tumor
   * No anticipated physical connection between post-resection tumor cavity and cerebral ventricle
   * Karnofsky performance status (KPS) ≥ 60 at time of surgery
   * No prior treatment of the tumor with gene or virus therapy, immunotherapy, brachytherapy, or implants of polymers containing chemotherapeutic agents (e.g. Gliadel Wafer)
   * No immunosuppressive or immune disorder
   * Baseline organ function testing intact
   * Patients who are candidates for surgical debulking (re-resection) following recurrence of diseases based on multidisciplinary evaluation by neurosurgeons, radiation oncologists, neuro-radiologists, and neuro-oncologists.
2. Subjects must have adequate baseline organ function, as assessed by the following laboratory values, within 30 days before initiating the study therapy:

   * Adequate renal function with creatinine clearance ≥ 50 mL/min/m2
   * Platelet count ≥ 100,000/μL
   * Absolute neutrophil count ≥ 1,000/μL
   * Hemoglobin \> 10.0 g/dL
   * Bilirubin \< 1.5 mg/dL; SGOT and SGPT \< 2.5 times upper limit of normal (ULN).
3. Women of child-bearing potential will be required to practice birth control for the duration of the treatment and for at least 90 days after surgery with intratumor virus inoculation. Men must use barrier protection for the duration of treatment and for at least 90 days after surgery with intratumor virus inoculation treatment.

Exclusion Criteria:

* Acute infection. Acute infection is defined by any viral, bacterial, or fungal infection that has required active treatment and caused oral temperature \>38.5oC and/or clinically significant leukocytosis
* Serum antibodies to human immunodeficiency virus (HIV)
* Previous history of liver disease including autoimmune or viral hepatitis
* Positive serologic test for Hepatitis B or C at baseline
* Immunosuppressive therapy except for corticosteroid use
* Serious medical or psychiatric illness or concomitant medication, which, in the judgment of the investigator, might interfere with the subject's ability to respond to or tolerate the treatment or complete the trial
* Impaired immunity or susceptibility to serious viral infections
* Pregnant or lactating females
* Allergy to any product used on the protocol
* Patient is not able to undergo a brain MRI.
* Patients who are not eligible for debulking surgery or resection of recurrent disease will be considered ineligible.

Where it's running

• Henry Ford Health System
  Detroit, Michigan, United States Recruiting

Study contacts

• Principal investigator: Tobias Walbert, MD, PhD — Henry Ford Health System
• Study coordinator: Tobias Walbert, MD, PhD
• Email: twalber1@hfhs.org
• Phone: 3139162723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using omental tissue to treat recurrent glioblastoma

  This study is testing whether using a piece of fat from the abdomen can help improve treatment for patients with recurrent glioblastoma by delivering medication and immune cells more effectively to the tumor site.

  Recruiting Northwell Health · New York, New York · NCT05979064

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Surgical technique to improve outcomes in glioblastoma patients

  This study is testing a new surgical method using special tissue flaps to see if it can help people with newly diagnosed glioblastoma live longer and have fewer problems after surgery.

  Recruiting Northwell Health · New York, New York · NCT05954858

• Combining eflornithine and temozolomide for newly diagnosed glioblastoma

  This study is testing a new combination of two medications, eflornithine and temozolomide, to find the best dose for people with newly diagnosed glioblastoma.

  Recruiting at 7 sites Phase 1 Orbus Therapeutics, Inc. · Birmingham, Alabama and 7 other locations · NCT05879367

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.